Literature DB >> 24974209

Mesalamine treatment mimicking relapse in a child with ulcerative colitis.

Iva Hojsak1, Ana M Pavić, Sanja Kolaček.   

Abstract

BACKGROUND: There are reports on mesalamine-induced bloody diarrhea mimicking ulcerative colitis (UC) relapse, mostly in adults.
METHODS: Herein we present a case of a child with UC who developed relapse of hemorrhagic colitis related to mesalamine.
RESULTS: A 10-year-old girl developed severe symptoms mimicking UC relapse 3 weeks after introduction of mesalamine therapy. After mesalamine was withdrawn, her symptoms improved, but deteriorated again during the challenge of mesalamine despite concomitant use of corticosteroids.
CONCLUSION: This is the first case report on such a young child during the concomitant use of corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24974209     DOI: 10.1007/s12519-014-0485-x

Source DB:  PubMed          Journal:  World J Pediatr            Impact factor:   2.764


  13 in total

1.  Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.

Authors:  Elizaveta Iofel; Anupama Chawla; Fredric Daum; James Markowitz
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-01       Impact factor: 2.839

2.  Diarrhea associated with mesalamine in a patient with chronic nongranulomatous enterocolitis.

Authors:  K D Fine; H E Sarles; B Cryer
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

3.  Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion.

Authors:  Maneesh Kumar Gupta; Scott Pollack; John J Hutchings
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-12-06

4.  Diarrhea as a side effect of mesalamine treatment for inflammatory bowel disease.

Authors:  F Goldstein; A J DiMarino
Journal:  J Clin Gastroenterol       Date:  2000-07       Impact factor: 3.062

5.  Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid.

Authors:  R Pamukcu; S B Hanauer; E B Chang
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

Review 6.  Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.

Authors:  E V Loftus; S V Kane; D Bjorkman
Journal:  Aliment Pharmacol Ther       Date:  2004-01-15       Impact factor: 8.171

7.  Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?

Authors:  C Scheurlen; H Allgayer; W Kruis; E Erdmann; T Sauerbruch
Journal:  Clin Investig       Date:  1993-04

8.  Mesalazine induced exacerbation of ulcerative colitis.

Authors:  K C Kapur; G T Williams; M C Allison
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines.

Authors:  Dan Turner; Arie Levine; Johanna C Escher; Anne M Griffiths; Richard K Russell; Axel Dignass; Jorge Amil Dias; Jiri Bronsky; Christian P Braegger; Salvatore Cucchiara; Lissy de Ridder; Ulrika L Fagerberg; Séamus Hussey; Jean-Pierre Hugot; Sanja Kolacek; Kaija Leena Kolho; Paolo Lionetti; Anders Paerregaard; Alexander Potapov; Risto Rintala; Daniela E Serban; Annamaria Staiano; Brian Sweeny; Gigi Veerman; Gabor Veres; David C Wilson; Frank M Ruemmele
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

10.  Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis.

Authors:  Yuichi Shimodate; Kunihiro Takanashi; Eriko Waga; Tomoki Fujita; Shinichi Katsuki; Masafumi Nomura
Journal:  Case Rep Gastroenterol       Date:  2011-04-12
View more
  1 in total

1.  Mesalamine Intolerance in Three Children with Crohn's Disease.

Authors:  Ceyda Tuna Kirsaclioglu; Zarife Kuloglu; Gonca Ustundag; Aydan Kansu; Erdal İnce; Arzu Ensari; Nurten Girgin
Journal:  Med Princ Pract       Date:  2015-12-02       Impact factor: 1.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.